How Wegovy works alongside insulin
Wegovy is a GLP-1 receptor agonist. It mimics the GLP-1 hormone that our body naturally produces in the gut after eating.
GLP-1 stimulates insulin release in a glucose-dependent manner, meaning it only boosts insulin when blood sugar is elevated.1 This is important because it differs from how injected insulin works. Injected insulin acts regardless of your blood sugar level, which is why combining it with Wegovy increases the risk of hypoglycaemia.
When you’re already on insulin, Wegovy’s key benefits come from its other functions. It slows gastric emptying, reduces glucagon secretion (which lowers the liver’s release of sugar into the bloodstream), and acts on the brain to reduce appetite.1
These combined effects promote weight loss, which can improve insulin sensitivity over time. As your body uses insulin more efficiently, your total insulin dose may decrease progressively during treatment.
Clinical evidence
SUSTAIN 5: semaglutide added to basal insulin
The SUSTAIN 5 trial studied 397 people with type 2 diabetes already on basal insulin, with or without metformin.
Participants received semaglutide 0.5 mg, semaglutide 1.0 mg, or placebo for 30 weeks.2
Semaglutide significantly outperformed placebo on both blood sugar control and weight loss.
HbA1c fell by 1.4% with 0.5 mg and 1.8% with 1.0 mg, compared to 0.1% with placebo.2
Participants lost 3.7 kg on the 0.5 mg dose and 6.4 kg on the 1.0 mg dose, compared to 1.4 kg on the placebo.
Insulin was reduced by 20% at the start of the trial, and hypoglycaemia wasn’t significantly higher in the semaglutide groups.2
SUSTAIN 11: semaglutide vs bolus insulin
SUSTAIN 11 compared semaglutide against insulin aspart (a mealtime insulin) in 1,748 adults already on basal insulin glargine.
This trial was investigating whether adding semaglutide is better than adding mealtime insulin.3
Semaglutide reduced HbA1c by 1.5% and body weight by 4.1 kg. Insulin aspart reduced HbA1c by 1.2% but increased body weight by 2.8 kg, a difference of 6.9 kg between the two approaches.3
These results showed that semaglutide can be more effective than adding bolus insulin, with weight loss rather than weight gain.
STEP 2: semaglutide 2.4 mg in type 2 diabetes
The STEP 2 trial studied semaglutide 2.4 mg (the Wegovy dose) in 1,210 adults with type 2 diabetes and a BMI of 27 or above.
Participants lost 9.6% of their body weight with semaglutide 2.4 mg, compared with 3.4% with placebo, over 68 weeks.4
Around 69% achieved at least 5% weight loss, and 50% achieved at least 10%. HbA1c fell by 1.6% with the 2.4 mg dose.4
Real-world evidence
Real-world data shows encouraging results. A retrospective study of insulin-treated patients with type 2 diabetes who started semaglutide found that 32.8% discontinued insulin entirely during follow-up, and 57.3% had their insulin dose reduced.5
These results don’t mean everyone will come off insulin. But it suggests that semaglutide, combined with weight loss and improved insulin sensitivity, can significantly reduce insulin requirements for many people.
Insulin dose adjustments
When you start Wegovy, your diabetes team will typically reduce your insulin dose proactively rather than waiting for hypoglycaemia to occur. The specific reduction depends on your current regimen and HbA1c level.
For basal insulin, a 10-20% dose reduction at initiation is common. The SUSTAIN 5 trial used a 20% reduction for participants with an HbA1c of 8.0% or below at baseline.2
For bolus (mealtime) insulin, reductions of 25-50% may be considered because the risk of hypoglycaemia around mealtimes is higher.
Semaglutide slows gastric emptying and reduces appetite, both of which affect post-meal blood sugar patterns.1
Your diabetes team will fine-tune your insulin dose based on your blood sugar readings as you escalate through the Wegovy dose steps. Each dose increase may need further insulin adjustments.
The MHRA has issued safety alerts about the risk of diabetic ketoacidosis (DKA) when insulin is rapidly reduced or discontinued in patients starting GLP-1 receptor agonists. Never stop insulin abruptly without medical supervision.1
Wegovy and insulin compared
|
Wegovy alone (no insulin) |
Wegovy + basal insulin |
Wegovy + basal-bolus insulin |
| Hypoglycaemia risk |
Low |
Moderate (requires dose reduction) |
Higher (requires significant dose reductions) |
| Typical insulin adjustment |
N/A |
Reduce basal by 10-20% |
Reduce basal by 10-20%, bolus by 25-50% |
| Blood sugar monitoring |
Standard |
More frequent during escalation |
Intensive monitoring recommended |
| Clinical evidence |
STEP 24 |
SUSTAIN 52 |
SUSTAIN 113 |
| NICE guidance |
TA875 (weight management)7 |
NG28 (specialist care)6 |
NG28 (consultant-led MDT)6 |
| DKA risk |
Very low |
Low if insulin isn’t stopped abruptly |
Moderate if insulin is reduced too aggressively |
Foods to focus on
Managing your diet on insulin and Wegovy together requires careful attention to what you eat and when.
When Wegovy reduces your appetite, you may eat less, which directly affects how much insulin you need. Your diabetes team should guide any changes to your eating pattern.1
Choosing high-fibre carbohydrates
If you’re on a basal-bolus insulin regimen, matching your insulin dose to your carbohydrate intake is one of the most important skills for blood sugar control.
Choosing complex carbohydrates over refined ones makes a real difference. Complex carbohydrates contain more fibre, which slows down digestion and the release of sugar into the bloodstream. This means fewer blood sugar spikes and steadier levels between meals.8
Good complex carbohydrate options include porridge oats, brown rice, sweet potato, wholegrain or sourdough bread, lentils, chickpeas, and most fruits. These are digested more slowly than white bread, white rice, or sugary cereals.8
If you’re on a fixed insulin dose (rather than an adjustable one), try to eat roughly the same amount of carbohydrate at similar times each day. This helps prevent mismatches between your insulin and food intake.8
Protein at every meal
Protein helps you feel fuller for longer and has minimal impact on blood sugar.
On Wegovy, protein becomes particularly important to avoid losing lean tissue (such as muscle and bone) while losing weight.
Good sources include chicken, turkey, fish, eggs, Greek yoghurt, tofu, beans, and lentils. Aim for a palm-sized portion at each meal.
Oily fish like salmon, mackerel, and sardines provide omega-3 fatty acids. Omega-3s may help reduce cardiovascular risk, which is particularly relevant for people with diabetes who already have elevated cardiovascular risk.9
Vegetables and balanced meals
Non-starchy vegetables, such as broccoli, spinach, peppers, courgettes, tomatoes, and green beans, are low in carbohydrates and rich in micronutrients. They can make up a large portion of your plate without significantly affecting blood sugar.
A helpful guide is to aim for:
- at least half your plate filled with vegetables,
- a quarter with protein,
- and a quarter with complex carbohydrates,
- plus a serving of healthy fats like olive oil, avocado, or nuts.
Foods to limit
Sugary drinks, fruit juices, sweets, and highly processed snacks cause rapid blood sugar spikes that are difficult to match with insulin. These are best kept for treating hypoglycaemia rather than as regular dietary choices.
Alcohol can unpredictably affect blood sugar. It may cause an initial rise followed by a delayed drop, increasing the risk of very low blood sugar levels.
If you drink, eat food alongside alcohol and monitor your blood sugar more closely.8
Managing reduced appetite on Wegovy
Wegovy can significantly reduce hunger. If you’re eating much less than usual, this can cause hypoglycaemia if your insulin dose hasn’t been adjusted downward. Never skip meals without discussing insulin dose changes with your diabetes team.
If nausea makes eating difficult, focus on small, frequent, nutrient-dense meals. Yoghurt, scrambled eggs, soup, and smoothies can be easier to tolerate than large meals. Stay hydrated, as dehydration can affect blood sugar readings.1
Physical activity
Exercise is one of the most effective tools for improving blood sugar control, but if you’re on insulin, it requires additional planning.
Physical activity increases the amount of sugar our muscles burn for energy, which can cause blood sugar to drop during or after exercise.10
Blood sugar management around exercise
If you’re on insulin, check your blood sugar before exercise. Aim for pre-exercise levels between 5.0 and 13.9 mmol/L. If below 5.0 mmol/L, eat 10-15 g of carbohydrate before starting.10
For prolonged activity (over 30-45 minutes), check blood sugar periodically during exercise.
Post-exercise hypoglycaemia can occur several hours after activity, so continue monitoring afterwards, particularly if you’ve exercised in the afternoon or evening.10
Your diabetes team may recommend reducing your insulin dose on days when you exercise. This depends on the type and intensity of activity, and whether you’re on basal-only or basal-bolus insulin.
Aerobic activity
Walking, cycling, swimming, and dancing all help the body to burn more sugar to support the activity, which helps to lower blood sugar levels over time.
Aim for at least 150 minutes per week of moderate-intensity aerobic activity, spread across at least three days.10
If you’re new to exercise, start with 10-15-minute walks after meals. Post-meal walking helps lower post-meal blood sugar spikes and is a practical starting point for most people.
Resistance training
Resistance training (using bodyweight exercises, resistance bands, or weights) helps build muscle mass.
More muscle means your body burns more sugar for energy throughout the day, which supports lower blood sugar levels over time. Aim for at least two sessions per week.10
Start with bodyweight exercises like squats, wall push-ups, and seated rows. Progress gradually, as the goal is to build a sustainable routine rather than train intensely from day one.
Practical tips for exercising on insulin
Carry a fast-acting carbohydrate source (glucose tablets, jelly babies, or a sugary drink) whenever you exercise.
Wear a medical ID that identifies you as an insulin user. If you use a continuous glucose monitor (CGM), set alerts for dropping blood sugar during activity.
Avoid injecting insulin into the muscle group you’re about to exercise, as this can speed up absorption and increase hypo risk. For example, avoid injecting into your thigh before cycling.10
Mental health
Living with diabetes and managing insulin therapy carries a significant psychological burden. This is an important aspect of diabetes care that’s often underrecognised.
Diabetes distress
Diabetes distress is distinct from clinical depression. It refers to the emotional burden of managing diabetes day-to-day: the frustration, overwhelm, and worry that come with constant self-management.
A meta-analysis of 55 studies found that 36% of people with type 2 diabetes experience significant diabetes distress.11
Contributors include the demands of blood sugar monitoring, carbohydrate counting, injection routines, and the fear of complications.
Adding Wegovy to your regimen introduces another medication to manage, but it may also ease distress by reducing insulin requirements over time.
Depression and anxiety
People with diabetes are around twice as likely to experience depression compared to those without. A meta-analysis found depression prevalence of 28% in women with diabetes and 18% in men.12
Depression can affect diabetes self-management, leading to missed insulin doses, poorer dietary choices, and reduced physical activity.
If you notice persistent low mood, loss of interest in activities, or difficulty coping, speak to your GP. Effective treatments are available.
Psychological insulin resistance
Many people experience anxiety about starting or intensifying insulin therapy. Research suggests 40-70% of patients experience some degree of reluctance towards insulin.13
Common fears include needle anxiety, worry about weight gain, fear of hypoglycaemia, and the belief that needing insulin means diabetes is getting worse. If you’re already on insulin, these fears may persist.13
Starting Wegovy alongside insulin can feel like another burden. However, many people find that the weight loss and reduced insulin requirements from Wegovy actually improve their overall relationship with diabetes management.
Fear of hypoglycaemia
Fear of hypoglycaemia is common in people on insulin. This can lead to deliberately running blood sugar higher than recommended to avoid hypos, a behaviour that increases the risk of long-term complications.14
If fear of hypoglycemia is affecting your daily life or sleep, discuss it with your diabetes team.
Continuous glucose monitors, insulin pump therapy, and structured education programmes can all help reduce hypoglycaemia risk and the anxiety around it.
Safety considerations
Hypoglycaemia
Hypoglycaemia is the primary safety concern when combining Wegovy with insulin.
Semaglutide alone rarely causes hypos because it stimulates insulin in a glucose-dependent way. But adding it to injected insulin changes the equation.1,2
Symptoms include shaking, sweating, confusion, dizziness, and a rapid heartbeat.
If you’re on insulin, you should already know how to recognise and treat a hypo, but the frequency may increase when you first start Wegovy.
Carry a fast-acting carbohydrate source at all times. This is especially important during the dose escalation phase, when your insulin dose may not yet be optimally adjusted.
Diabetic ketoacidosis
DKA occurs when the body doesn’t have enough insulin and starts breaking down fat too quickly, producing ketones. It’s more commonly associated with type 1 diabetes, but can occur in type 2 if insulin is withdrawn too rapidly.1
If you feel unwell, experience persistent nausea or vomiting, or notice fruity-smelling breath, seek medical attention immediately. Never stop insulin abruptly without medical supervision.
Diabetic retinopathy
Rapid improvements in blood sugar control can temporarily worsen diabetic retinopathy. This has been observed with semaglutide in clinical trials and is related to the speed of blood sugar improvement rather than the medication itself.1
If you have existing retinopathy, your diabetes team should arrange appropriate eye monitoring before and during treatment.
Some weight management services may not accept people with active diabetic retinopathy, so discuss this with your prescriber before starting.
Gastrointestinal side effects
Nausea, vomiting, diarrhoea, and constipation are common during Wegovy dose escalation. If you’re on insulin, vomiting is particularly important to manage because it can affect food intake and blood sugar unpredictably. Contact your diabetes team if you can’t keep food down.1
When to speak to your GP
Contact your GP or diabetes team if you experience:
- Frequent or severe hypoglycaemia episodes (shaking, sweating, confusion, dizziness)
- Symptoms of DKA (persistent nausea, vomiting, abdominal pain, fruity-smelling breath)
- Changes in your vision, which could indicate retinopathy progression
- Persistent vomiting that prevents you from eating or taking medications
- Blood sugar readings consistently outside your target range despite adjustments
- Severe abdominal pain, which could indicate pancreatitis (rare but serious)
- Persistent low mood, anxiety, or difficulty coping with diabetes management
NICE NG28 recommends that GLP-1 receptor agonist and insulin combinations should only be offered with specialist care or under a consultant-led multidisciplinary team.6 If you’re managing this combination through your GP alone, ask about referral to a specialist diabetes service.
Frequently asked questions
Is it safe to take Wegovy with insulin?
Yes, it’s safe when managed properly by your diabetes team. The main requirement is to reduce your insulin dose when starting Wegovy to prevent hypoglycaemia.
Clinical trials have studied this combination and found it effective and well-tolerated when insulin is adjusted appropriately.2
How much should my insulin dose be reduced when starting Wegovy?
This depends on your insulin regimen and current blood sugar control. For basal insulin, a 10-20% reduction at initiation is typical.
For bolus insulin, reductions of 25-50% may be considered. The SUSTAIN 5 trial used a 20% reduction in basal insulin for participants with an HbA1c of 8.0% or below.2
Will I still need insulin if I take Wegovy?
Many people will still need insulin, but at reduced doses. Real-world data suggest that around a third of insulin-treated patients with type 2 diabetes discontinued insulin after starting semaglutide.5
Whether you can reduce or stop insulin depends on your individual circumstances and should be guided by your diabetes team.
Can Wegovy replace insulin for type 2 diabetes?
Wegovy isn’t a direct replacement for insulin. They work through different mechanisms.
However, the weight loss and improved insulin sensitivity from Wegovy can significantly reduce insulin requirements.
Some people may eventually come off insulin, but this should never be attempted without medical supervision.
What foods should I focus on while taking insulin and Wegovy?
Focus on complex carbohydrates that are high in fibre (porridge, brown rice, sweet potato, lentils), protein at every meal, and plenty of non-starchy vegetables.
If you’re on a basal-bolus regimen, matching your insulin to your carbohydrate intake is essential. When Wegovy reduces your appetite, tell your diabetes team so they can adjust your insulin dose.8
Can I exercise while on insulin and Wegovy?
Yes, and exercise is recommended. Check your blood sugar before, during (for prolonged activity), and after exercise. Carry a fast-acting carbohydrate source. Your diabetes team may advise reducing your insulin dose on days you exercise. Start gradually and build up over time.10
What are the signs of hypoglycaemia I should watch for?
Common symptoms include shaking, sweating, anxiety, confusion, dizziness, hunger, and a rapid heartbeat. In severe cases, you may experience blurred vision, difficulty speaking, or loss of consciousness. Treat immediately with a fast-acting carbohydrate and check your blood sugar.
Can I take Wegovy with both basal and bolus insulin?
Yes, but this combination requires the most careful management. SUSTAIN 11 studied semaglutide alongside basal insulin and found it was more effective than adding bolus insulin.3 Your diabetes team may consider replacing bolus insulin with semaglutide rather than adding it on top.
Does NICE recommend Wegovy alongside insulin?
NICE NG28 states that GLP-1 receptor agonist and insulin combinations should only be offered with specialist care or a consultant-led multidisciplinary team.6
NICE TA875 covers Wegovy specifically for weight management and doesn’t exclude people on insulin, but the combination requires specialist oversight.7
How does diabetes distress differ from depression?
Diabetes distress is the emotional burden of daily diabetes management: frustration with monitoring, injection routines, and fear of complications. It affects around 36% of people with type 2 diabetes.11
Depression is a broader mental health condition. Both can coexist, and both deserve support from your healthcare team.
Take home message
Taking Wegovy while on insulin is safe and well-supported by clinical evidence, but it requires careful management.
The most important steps are reducing your insulin dose at initiation, monitoring your blood sugar closely during escalation, and working with a specialist diabetes team throughout.
The clinical data are encouraging. Semaglutide added to basal insulin produces significant improvements in both blood sugar control and weight, and real-world evidence suggests that around a third of insulin-treated patients may eventually discontinue insulin.2,5
Paying attention to your diet (particularly choosing complex, high-fibre carbohydrates and prioritising protein), staying active, and looking after your mental health are all important parts of managing this combination effectively.
If you’re considering Wegovy and you’re currently on insulin, speak to your diabetes team about whether it’s appropriate for you.
Second Nature’s programme combines medication support with personalised nutrition and lifestyle guidance from registered dietitians and nutritionists, built around a balanced plate approach that’s flexible and sustainable.
A peer-reviewed study published in JMIR Formative Research found that active subscribers on Second Nature’s semaglutide-supported programme lost an average of 19.1% of their body weight at 12 months, with 77.7% achieving at least 10% weight loss.15
This support can help you build sustainable habits around food, movement, and wellbeing alongside your insulin therapy.
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
References
- Electronic Medicines Compendium. (2026). Wegovy summary of product characteristics.
- Rodbard, H.W. et al. (2018). Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomised, controlled trial. The Journal of Clinical Endocrinology & Metabolism, 103(6), 2291-2301.
- Kellerer, M. et al. (2022). Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11). Diabetes, Obesity and Metabolism, 24(9), 1788-1799.
- Davies, M. et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet, 397(10278), 971-984.
- Bethel, M.A. et al. (2024). Insulin discontinuation and dose reduction in patients with type 2 diabetes initiating semaglutide: a retrospective cohort study. Journal of Diabetes Science and Technology.
- NICE. (2022). Type 2 diabetes in adults: management (NG28).
- NICE. (2023). Semaglutide for managing overweight and obesity (TA875).
- Diabetes UK. (2024). Carbohydrates and diabetes.
- American Diabetes Association. (2025). Standards of Care in Diabetes 2025: facilitating positive health behaviours and well-being to improve health outcomes. Diabetes Care, 48(Supplement 1), S86-S127.
- Colberg, S.R. et al. (2016). Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care, 39(11), 2065-2079.
- Perrin, N.E. et al. (2017). The prevalence of diabetes-specific emotional distress in people with type 2 diabetes: a systematic review and meta-analysis. Diabetic Medicine, 34(11), 1508-1520.
- Anderson, R.J. et al. (2001). The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care, 24(6), 1069-1078.
- Diabetes UK. (2021). Emotional health professionals guide: chapter 5, fear of insulin.
- Martyn-Nemeth, P. et al. (2016). Fear of hypoglycaemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for prevention. Journal of Diabetes and its Complications, 30(1), 167-177.
- Richards, R. et al. (2025). A remotely delivered, semaglutide-supported weight management program: 12-month outcomes from a retrospective service evaluation. JMIR Formative Research, 9(1), e72577.
